Application No.: 09/523,776 2 Docket No.: 49632(71699)

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions of claims in the application.

Claims 1-44. (cancelled)

Claim 45. (previously presented) A method for treating a mammal suffering from cystic fibrosis, comprising:

administering to the mammal a therapeutically effective amount of at least one compound of the following Formula I:

wherein each W comprises an unsaturated straight carbon chain and is independently optionally substituted alkylene; optionally substituted alkenylene; optionally substituted heteroalkylene; optionally substituted heteroalkynynylene; or optionally substituted heteroalkynynylene;

each Y is independently a carboxy acid, ester, sulfonic acid, nitro, cyano or haloalkyl;

each R is independently halogen, cyano, nitro, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted carbocyclic aryl; optionally substituted aralkyl;

m is an integer of from 1 to 6; n is an integer of from 0 to 5; and pharmaceutically acceptable salts thereof,

wherein the compound comprises a straight carbon chain of four carbon atoms, and with the exclusion of 4-phenylbutyric acid.

Application No.: 09/523,776

3

Docket No.: 49632(71699)

Claim 46. (previously presented) The method of claim 45 wherein the compound comprises a carbon-carbon double bond in the second ( $\Delta 2$ ) or third ( $\Delta 3$ ) position of the chain.

Claim 47. (previously presented) The method of claim 45 wherein the compound further comprises a phenyl ring in the fourth position of the chain.

Claim 48. (previously presented) The method of claim 45 wherein the compound is 4-phenyl- Δ3-transbutenoic acid or a pharmaceutically acceptable salt thereof.

Claim 49. (previously presented) The method of claim 45 wherein the compound is 4-phenyl-  $\Delta 2$ -transbutenoic acid or a pharmaceutically acceptable salt thereof.

Claim 50. (previously presented) The method of claim 45, wherein the compound is 4-phenyl-  $\Delta$ 3-transbutenoate or 4-phenyl-  $\Delta$ 2-transbutenoate.

Claim 51. (previously presented) The method of claim 45 wherein the mammal is identified as suffering from cystic fibrosis and the compound is administered to the identified mammal.

Claim 52. (previously presented) The method of claim 48 wherein the mammal is identified as suffering from cystic fibrosis and the compound is administered to the identified mammal.

Claim 53. (previously presented) The method of claim 49 wherein the mammal is identified as suffering from cystic fibrosis and the compound is administered to the identified mammal.

Application No.: 09/523,776

4

Docket No.: 49632(71699)

Claim 54. (previously presented) The method of claim 50 wherein the mammal is identified as suffering from cystic fibrosis and the compound is administered to the identified mammal.